Wednesday, October 19, 2016

Gopher Protocol (OTCQB: $GOPH) Begins Building of Initial 50 Guardian Sphere Devices – Initial Market for Tracking Pets

Gopher Protocol (OTCQB: $GOPH) Begins Building of Initial 50 Guardian Sphere Devices – Initial Market for Tracking Pets



SAN DIEGO, CA - October 19, 2016 (Investorideas.com Newswire) Gopher Protocol Inc. (OTCQB:GOPH) ("Gopher" and the "Company"), a development-stage company which specializes in the development of real-time, heuristic-based mobile technologies, and its partner, Guardian Patch LLC ("Guardian"), announced today that they are in the process of creating their initial 50 Guardian Sphere devices, which, if completed, will be tested in the U.S. as complete systems. As previously announced on September 21st, the Company and Guardian are currently ramping-up their efforts for the release of their Guardian Sphere tracking device, of which there is no guarantee, which is primarily designed for pets, but may also be used for tracking children, adults, including the disabled, inventory, artwork or virtually any object located within an area covered by the device.

The Guardian Sphere (the "Sphere") system is a derivative technology of the Company's Guardian Patch technology. The Sphere is designed to provide its users with local tracking capability using a re-chargeable/replaceable battery source. The objective of the Company's current efforts, which the Company hopes to achieve, is to deliver for testing in a pre-designated area 50 Guardian pet devices along with a base station, test results and eventual manufacturing capability for both the mobile and the base unit.

The Sphere is an innovative tracking device that can easily be attached to a pet's collar and then transmit real-time location information to the smartphone(s) or website account of the registered owner of the device. The Sphere has a replaceable battery and operates on the exclusive Guardian private network, which provides owners with the unique ability to obtain real-time tracking information without the need for GPS, Wi-Fi or cellular service. The Sphere includes state of the art radio technology, a GPS system and micro controller systems, with a potential "back-up" Bluetooth unit. The Sphere sends signals in specific intervals to report on its location. The Sphere's system analyzes the information using its proprietary, advanced mathematical modeling software that precisely calculates the Sphere's location. The Sphere's mobile application then presents the exact location of the Sphere on the map. An additional unique system feature is the Sphere's Emergency Alert system. Users of the Sphere have the ability to transmit emergency alerts directly from their mobile apps, which transmit their Sphere locations. All registered users located in such a Sphere's proximity will be notified about the Emergency and may notify the user about the Sphere's recovery (which we fondly refer to as a "private emergency alert").

The Sphere utilizes a bi-directional system which enables data transmission/receiving acknowledgment. It also includes error correction protocol to ensure data accuracy. The Sphere has its own battery source and may be plugged into external power using a standard Android type charger socket. The Sphere also comes with its own ID. This ID is registered on the mobile app to track the Sphere's location. Multiple Spheres can be registered on the same app for multiple tracking.

"The actual creation of our initial 50 Spheres along with their suggested final design is extremely exciting. These 50 Spheres will be tested as a complete system in San Diego, Los Angeles and San Francisco. We believe tests will be initiated by mid-November. Our goal in developing the Sphere is to provide pet owners with peace of mind through the use an invaluable recovery tool which could enable them to track their pets in real-time should they ever become separated," stated Company CTO, Dr. Danny Rittman.

At the time of this press release, the Company has not specified a sale release date for the Sphere. The Company is committed to providing more definitive release date information in the coming weeks and is targeting a release date of approximately Q1 2017, of which there is no guarantee.


About Guardian Patch
The Guardian Patch (the "Patch"), potentially arriving in consumer markets in 2017, is a unique location technology that works with or without GPS.  The Patch is a "stick-on" device that provides its users with the capability to protect and track objects, a loved-one or even a pet, through a mobile application.  Download the Patch app, register your patch, and track it on your mobile device or on our designated website.  Register the Patches of your family members and friends to receive alerts in the event of an emergency.  Peel the Patch off and the Patch acts as a beacon, sending out a signal and notifying anyone who has registered the user's Patch.

About Gopher Protocol Inc.
Gopher Protocol Inc. (OTCQB: GOPH) (“Gopher” and the "Company") (http://gopherprotocol.com/) is a development-stage company developing a real-time, heuristic-based mobile technology.  Upon development, the technology will consist of a smart microchip, mobile application software and supporting software that will run on a server.  The system contemplates the creation of a global network.  Gopher believes this will be among the first system that is developed using a human, heuristic-based analysis engine.  Since the core of the system will be its advanced microchip technology that will be capable of being installed in any mobile device worldwide, Gopher expects that this will result in an internal, private network between all mobile devices utilizing the microchip by providing mobile technology for computing power enhancement, advanced mobile database management/sharing and other additional mobile features.

Corporate Site: http://gopherprotocol.com
Consumer and product website for Guardian Patch: http://www.guardianpatch.com/.

Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements".  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact:
Danny Rittman CTO
Gopher Protocol Inc.
VM Only - 888-685-7336

Visit this company: http://gopherprotocol.com/

More info on GOPH at Investorideas.com Visit: http://www.investorideas.com/CO/GOPH/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GOPH is a PR , social media and publishing client and compensates Investorideas.com (effective April 4, 2016 - three thousand five hundred per month) More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.






Actinium (NYSE: $ATNM) Announces Acceptance of Actimab-A Data for Poster Presentation at American Society of Hematology Annual Meeting

Actinium (NYSE: $ATNM) Announces Acceptance of Actimab-A Data for Poster Presentation at American Society of Hematology Annual Meeting



NEW YORK - October 19, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that data from the Company’s Actimab-A program, Actinium's most advanced alpha particle immunotherapy program intended for newly diagnosed AML patients over the age of 60, has been selected by the American Society of Hematology (ASH) Program Committee for poster presentation at the 58th Annual Meeting in San Diego, California on December 5, 2016.

Title: Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Abstract: #4050

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III

Location: San Diego Convention Center, Hall GH

Presentation: December 5, 6:00 PM - 8:00 PM

Abstracts are expected to be available at www.hematology.org on November 3, 2016 at 9:00 am Eastern time. In addition, the abstracts will be published online in the December 3, 2015 supplemental volume of Blood.


About Actimab-A
Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) program, is in a Phase 2 clinical trial for patients newly diagnosed with AML over the age of 60. Actimab-A is being developed as a first-line therapy and it has attracted support from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy profile. Actimab-A consists of the monoclonal antibody, HuM195, and the radioisotope, actinium-225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. HuM195 is the humanized version of M195 and is a monoclonal antibody that targets CD33, which is abundantly found on myeloid leukemia cells. Both the alpha particle technology and HuM195 were initially developed at Memorial Sloan Kettering Cancer Center. Actimab-A is a second-generation therapy from the Company’s HuM195-Alpha program, which has now been studied in almost 90 patients in four clinical trials.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is in a 53 patient, multicenter, open-label Phase 2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:
Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.






Tuesday, October 18, 2016

Actinium Pharmaceuticals (NYSE: $ATNM) Granted Orphan Designation from the European Medicines Agency for Iomab-B

Actinium Pharmaceuticals (NYSE: $ATNM) Granted Orphan Designation from the European Medicines Agency for Iomab-B

·        Orphan designation is expected to provide increased communication and guidance from regulators and 10-year market exclusivity should marketing authorization be obtained
·        Orphan designation for Iomab-B follows SME (small or medium-sized enterprise) status, which was granted in August 2016
·        Iomab-B now has orphan designation in the US and EU


NEW YORK - October 18, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company’s lead asset, Iomab-B, has been granted orphan designation in the European Union (EU) by the European Medicines Agency (EMA).

Iomab-B is intended to be used, upon approval, in preparing patients with relapsed or refractory Acute Myeloid Leukemia (AML) who are over the age of 55 for a bone marrow transplant (BMT), often referred to as a hematopoietic stem cell transplant (HSCT). Iomab-B is currently in a 150 patient multicenter, pivotal Phase 3 trial that is being conducted in the United States.

"We are excited to have been granted orphan designation in the EU for Iomab-B, which comes in addition to the SME status Actinium was granted and orphan designation for Iomab-B in the U.S.," stated Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals. "We believe Iomab-B represents a potentially revolutionary therapy for relapsed or refractory AML patients who are over the age of 55 who could benefit from a bone marrow transplant, which is a drastically underserved patient population. With additional regulatory support for Iomab-B in the EU through orphan designation and SME status we hope to one day bring Iomab-B to the patients of the EU."

The EMA grants orphan designation to rare diseases that are defined as life-threatening or chronically debilitating conditions that affect no more than 5 in 10,000 people in the EU. With an estimated 30 million people living in the EU this equates to approximately 250,000 people or less for each rare disease.


About Iomab-B
Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is in a 53 patient, multicenter, open-label Phase 2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:
Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.




Friday, October 14, 2016

Investorideas Sector Updates in #Mining, #Technology, #Gaming & #Energy Stocks


#TSX #Mining #Stocks $GBL.V, $CUZ.V, $BWR.V, $ABN.V Added to #Investorideas

Investorideas Sector Updates in #Mining, #Technology, #Gaming & #Energy Stocks



Point Roberts, WA, Delta BC – October 14, 2016 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its global stock directories within mining, technology, gaming & energy stocks.

Mining additions included TSX Venture stocks exploring in Canada, the USA and West Africa along with a CSE stock Augustine Ventures Inc. (CSE: WAW), currently involved in a joint venture with Red Pine Exploration (TSX:RPX.V) and Citibar, LLP.

Also added this week is technology stock iGambit, Inc. (OTCQB: IGMB), which provides financial and technical support for small-to-medium sized tech companies such as ArcMail, an email archiving and management solutions company. 

Also new this week are online gaming/gambling stock VGambling Inc. (OTC: GMBL) and energy company Parkland Fuel Corporation (TSX: PKI.TO), an independent marketer of fuel and petroleum products including gasoline, diesel, propane, lubricants, heating oil and other high-quality petroleum products.


Mining Companies Added:
GB Minerals Ltd. (TSX:GBL.V), Cruz Capital Corp (TSX:CUZ.V), BWR Exploration Inc. (TSX:BWR.V), Aben Resources Ltd. (TSX:ABN.V) and  Augustine Ventures Inc. (CSE: WAW)
   
Technology Companies Added:
iGambit, Inc. (OTCQB: IGMB) is a fully reporting publicly-held company. We are a diversified company pursuing specific technology strategies and objectives. These objectives have included, among others, the acquisition of early-stage technology companies with strong growth potential easily recognized in the public arena. We believe that the background of our management and of our Board of Directors in the technology markets is a valuable resource that makes us a desirable business partner. We expect to work to assume an active role in the development and growth of the new company, providing both strategic guidance and operational support. The management of iGambit believes that it can leverage its collective expertise to help position the combined company to produce high-margin, recurring and predictable earnings and generate long-term value for our stockholders.

Gaming/Gambling Companies Added:
VGambling Inc. (OTC: GMBL) is a next generation online gambling company specifically focused on eSports. VGambling intends to offer wagering on eSports events on a fully licensed, regulated and secured platform to the global eSports audience, excluding the United States. In addition, VGambling intends to offer users from around the world the ability to participate in multi-player video games tournaments online for cash prizes. VGambling is led by a team of industry and technical experts from the online gambling and video game industries, e-Sports, marketing, legal and financial professionals. The Company maintains offices in St. Mary's, Antigua and Barbuda. VGambling is currently developing several play money websites and their real money wagering website. VGambling common stock is listed on the OTCQB under the symbol GMBL. For more information, please see www.vgambling.net

Energy Companies Added:
Parkland Fuel Corporation (TSX: PKI.TO) is one of North America's fastest growing independent marketers of fuel and petroleum products. We deliver gasoline, diesel, propane, lubricants, heating oil and other high-quality petroleum products to motorists, businesses, households and wholesale customers in Canada and the United States. Our mission is to be the partner of choice for our customers and suppliers, and we do this by building lasting relationships through outstanding service, reliability, safety and professionalism.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411




Thursday, October 13, 2016

Gainey (TSXV: $GNC; OTCQX: $GNYPF) Continues to Drill New Zones at La Higuerita Within the 'El Colomo Gold-Silver Project' in Mexico

Gainey (TSXV: $GNC; OTCQX: $GNYPF) Continues to Drill New Zones at La Higuerita Within the 'El Colomo Gold-Silver Project' in Mexico



Vancouver, British Columbia - October 13, 2016 (Investorideas.com Newswire) Gainey Capital Corp. (TSXV: GNCOTCQX: GNYPF) is pleased to announce the continuation of the Company's Phase 1 drilling program of an additional three holes at the 'La Higuerita Gold-Silver mineralized zone' ("La Higuerita") located in the Sierra Madre Occidental Trend in Western Mexico.

La Higuerita is a part of Gainey's 100% owned, 187 km2 El Colomo Gold-Silver project that hosts 21 highly prospective, gold-silver mineralized zones located within the Sierra Madre Golden Belt, Mexico. The Company is currently in the process of drill testing at La Higuerita which has encountered the following surface samples, located in Table 1 below, that appear on the Gainey news release disseminated on October 06, 2015:

Surface Sample Highlights:



Gainey recently announced the drilling results from the ‘La Nueva Victoria mineralized zone' which can be seen in Table's 2 and 3 below:

Surface Sample Highlights:


*Au Equivalent calculated using a price of $1,300 US/oz for gold and $18 US/oz for silver.



*Au Equivalent calculated using a price of $1,300 US/oz for gold and $18 US/oz for silver.

Rafael Gallardo, Senior Geologist of Minera Cascabel S.A. de C.V., who is leading the drill program, commented, "The target of ‘La Higuerita mineralized zone' host the same characteristics of mineralization and alteration as was encountered at the La Nueva Victoria target and all three zones are part of the Golden Corridor. These two targets have strong potential to find veins of high grade values hosted in felsic dykes and permeable lithic tuff. We are very excited to drill these two additional targets."

David Coburn, CEO of Gainey, commented, "we are very encouraged by the success and drill results that have been encountered at the near-surface, La Nueva Victoria mineralized zone. As we continue to move forward with our Phase 1 drilling program on La Higuerita, we are most encouraged by the fact that the Company's El Colomo Project hosts a further 19, drill-ready, prospective gold-silver mineralized zones that Gainey plans on drill-testing in the near future."

El Colomo Property
El Colomo is a highly prospective, 187 km2 property with district-scale gold-silver potential located within the ‘Golden Corridor' in Sierra Madre, Mexico. High-grade and bulk tonnage targets have already been identified through prior exploration and there are strong indications of continuity between La Higuerita, La Nueva Victoria and El Arrayan (at least 2 km in strike length).

97% of this 18,766-hectare project has not been explored using modern concepts & technology. All 21 mineralized zones identified to date are located in the central portion of the property and within a 1.5 km radius of each other.

Qualified Person
David Hladky, P. Geo. is the Qualified Person with respect to NI 43-101 at El Colomo.


About Gainey Capital Corp.
Gainey Capital is a gold and silver exploration, development and mineral processing company exploring an aggregate of 187-km2 strategically located in the gold/silver-rich Sierra Madre Occidental Trend in western Mexico. The company’s processing center, located outside of Huajicori, in Nayarit, Mexico, is capable of processing up to 300 tons of mineralized material per day and the company has the capability to upgrade to 600 tons per day with a low capital expenditure.  Additional information on Gainey Capital, its current operations and its vision is available on the Company’s website at www.gaineycapital.com or from info@gaineycapital.com.


ON BEHALF OF THE BOARD OF DIRECTORS

    “David Coburn”
David Coburn, Chief Executive Officer

For information, please contact the Company:
Phone: 480-347-8904    

FORWARD LOOKING STATEMENTS: This press release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date such statements were made. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
           
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has reviewed or accepts responsibility for the adequacy or accuracy of this Release.

Visit this company: www.gaineycapital.com

More info on GNC.V at Investorideas.com Visit: http://www.investorideas.com/CO/GNC/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure : Gainey Capital Corp. has retained Investor ideas for 3 months starting September 16 2016 for news and social media marketing ; three thousand six hundred plus stock options - see more info at http://www.investorideas.com/About/News/Clientspecifics.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.





Monday, October 10, 2016

NXT-ID, Inc. (NASDAQ: $NXTD) releases preliminary results for the quarter ended September 30, 2016

NXT-ID, Inc. (NASDAQ: $NXTD) releases preliminary results for the quarter ended September 30, 2016



MELBOURNE, Florida - October 10, 2016 (Investorideas.com Newswire) NXT-ID, Inc. (NASDAQ:NXTD) (NXTDW) ("NXT-ID" or the "Company"), a company focused on the growing mobile commerce market announces selected preliminary results for the quarter ended September 30, 2016.

Revenues were approximately $3,000,000 for the three months ended September 30, 2016 compared to $418,128 for the same period in 2015. Revenues from the recent LogicMark acquisition were included from July 25, 2016, and accounted for approximately 90% of the increase from the comparative period in 2015. The operating loss for the three months ended September 30, 2016 narrowed to approximately $500,000 compared to an operating loss of $3,003,496 for the same period in 2015. The net loss for the three months ended September 30, 2016 was approximately $1,500,000 after approximately $1,000,000 in interest expense compared to a net loss of $3,543,313 for the three months ended September 30, 2015.

"Our recent acquisition, LogicMark, has performed well since July 25, 2016 and was a major contributor to the improved results," said Gino Pereira, Chief Executive Officer of NXT-ID, Inc. "We also continue to make good progress on our collaboration with WorldVentures to develop their innovative smart card. We are planning to commence deliveries on the outstanding $15 million purchase order in the last quarter of 2016. We expect the last quarter of 2016 to show continued improved results as we will have a full quarter contribution from LogicMark as well as smart card deliveries to WorldVentures."

Preliminary Results
The results provided in this press release are preliminary and subject to completion and review of Nxt-ID's 2016 third quarter financial statements in conjunction with the Company's 2016 third quarter Form 10-Q filing, and therefore they are subject to change. Nxt-ID intends to report final results for the 2016 third quarter on or about November 14, 2016, after market close. Nxt-ID's earnings press release and prepared remarks reviewing its financial results and guidance will be made available on the Investor Relations section of its website.


About NXT- ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s innovative MobileBio® solution mitigates consumer risks associated with mobile computing, M-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio suite of biometric solutions that secure consumers' mobile platforms. With extensive experience in Biometric Identity Verification, Security and Privacy, Encryption and Data Protection, Payments, Miniaturization and Sensor technologies, the Company partners with industry leading companies to provide solutions for modern payment and IoT applications.

Forward-Looking Statements for NXT-ID: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

NXT- ID Inc Contact:
Corporate info: info@nxt-id.com

Media:
D. Van Zant
+1-800-665-0411
press@nxt-id.com

Visit this company: nxt-id.com; 3d-id.net; wocketwallet.com/

More info on NXTD at Investorideas.com Visit: http://www.investorideas.com/CO/NXT/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.  Disclosure: Nxt-ID, Inc. (NXTD)  is a long term paid news publication and PR client of Investorideas.com. Renewed October 1, 2016 – see details at http://www.investorideas.com/About/News/Clientspecifics.asp